Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.
| Revenue (Most Recent Fiscal Year) | $25.98B |
| Net Income (Most Recent Fiscal Year) | $5.89B |
| PE Ratio (Current Year Earnings Estimate) | 14.53 |
| PE Ratio (Trailing 12 Months) | 14.12 |
| PEG Ratio (Long Term Growth Estimate) | 2.05 |
| Price to Sales Ratio (Trailing 12 Months) | 5.13 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 55.90 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 10.71 |
| Pre-Tax Margin (Trailing 12 Months) | 28.40% |
| Net Margin (Trailing 12 Months) | 24.92% |
| Return on Equity (Trailing 12 Months) | 218.34% |
| Return on Assets (Trailing 12 Months) | 16.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 14.76 |
| Inventory Turnover (Trailing 12 Months) | 1.49 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.52 |
| Earnings per Share (Most Recent Fiscal Quarter) | $4.65 |
| Earnings per Share (Most Recent Fiscal Year) | $17.10 |
| Diluted Earnings per Share (Trailing 12 Months) | $11.80 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 534.93M |
| Free Float | 532.47M |
| Market Capitalization | $135.42B |
| Average Volume (Last 20 Days) | 2.43M |
| Beta (Past 60 Months) | 0.56 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.46% |
| Percentage Held By Institutions (Latest 13F Reports) | 79.01% |
| Annual Dividend (Based on Last Quarter) | $7.76 |
| Dividend Yield (Based on Last Quarter) | 3.07% |